CHIMERIC MONOCLONAL ANTI-GD2 ANTIBODY 14.18 IN METASTATIC MELANOMA

嵌合单克隆抗 GD2 抗体 14.18 用于治疗转移性黑色素瘤

• 批准号: 3783481
• 负责人: MANSOOR N SALEH
• 金额: --
• 依托单位: UNIVERSITY OF ALABAMA AT BIRMINGHAM
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3783481
• 关键词: clinical trials; drug tolerance; human subject; human therapy evaluation; hybrid antibody; immune tolerance /unresponsiveness; immunotoxicity; melanoma; metastasis; monoclonal antibody; neoplasm /cancer immunotherapy; pharmacokinetics

This is a phase I study of the chimeric anti-GD2 MoAB 14.18 in patients with melanoma. Toxicity, MTD, pharmacokinetics and immune response are being studied.

这是嵌合抗GD2单抗14.18在患者中的I期研究 患有黑色素瘤。毒性、MTD、药代动力学和免疫反应 正在研究中。